Retatrutide, also known by its development code LY3437943, is an investigational triple receptor agonist being studied for obesity and type 2 diabetes. Developed by Eli Lilly and Company, it simultaneously targets GLP-1, GIP, and glucagon receptors — a mechanism that distinguishes it from currently approved therapies such as semaglutide and tirzepatide. As of mid-2025, retatrutide has not received marketing authorisation from the MHRA, EMA, or any other regulatory body. This article explains the other names for retatrutide, its development status, and what patients and clinicians in the UK need to know.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors to address multiple aspects of metabolic dysfunction. It remains unapproved as of mid-2025, with long-term safety and efficacy still under investigation in Phase 3 trials.

Retatrutide is an investigational drug currently under clinical development for the treatment of obesity and type 2 diabetes mellitus. It belongs to a novel class of agents known as triple receptor agonists, distinguishing it from earlier-generation weight-loss medications. Specifically, retatrutide simultaneously activates three incretin and metabolic hormone receptors:

• GLP-1 (glucagon-like peptide-1) receptor — promotes insulin secretion, reduces appetite, and slows gastric emptying

• GIP (glucose-dependent insulinotropic polypeptide) receptor — enhances insulin release and may support fat metabolism

• Glucagon receptor — preclinical and early clinical data suggest this may increase energy expenditure and promote hepatic fat breakdown, though glucagon receptor agonism can also raise blood glucose levels and the full implications in humans are still being characterised

This triple mechanism of action is hypothesised to produce meaningful reductions in body weight by addressing multiple aspects of metabolic dysfunction. It is important to note that no head-to-head clinical trials comparing retatrutide directly with dual agonists such as tirzepatide (which targets GLP-1 and GIP) or single GLP-1 receptor agonists such as semaglutide have been conducted. Cross-trial comparisons are unreliable, and any claims about superior efficacy relative to existing therapies should be interpreted with caution. Whether retatrutide offers advantages over currently approved agents for outcomes such as insulin resistance, dyslipidaemia, or cardiovascular risk is being studied in ongoing trials.

Early-phase clinical trial data, including results from a Phase 2 trial published in The New England Journal of Medicine in 2023, demonstrated substantial weight reductions — in some participants exceeding 20% of body weight over 48 weeks — alongside a broadly manageable short-term adverse effect profile. These findings have generated considerable scientific interest. However, as of mid-2025, retatrutide has not received regulatory approval in the UK or elsewhere. Its long-term safety profile, optimal dosing, and broader clinical utility remain under investigation in ongoing Phase 3 trials. Approval timing is unknown and will depend on the results of these trials and subsequent regulatory review.

Brand Names, Generic Names and Development Codes for Retatrutide

Retatrutide has no approved brand name; its official INN is retatrutide and its Eli Lilly development code is LY3437943. These are the only formally recognised names — any brand names seen online are not regulatory-sanctioned.

Understanding the other names for retatrutide is important for patients and clinicians who may encounter this compound referenced differently across scientific literature, clinical trial registries, and pharmaceutical communications. As of mid-2025, retatrutide does not have an approved brand name, as it has not yet received marketing authorisation from any regulatory body, including the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK or the European Medicines Agency (EMA).

The names and codes currently associated with retatrutide include:

• International Nonproprietary Name (INN): Retatrutide — this is the official generic name assigned by the World Health Organisation (WHO) and recorded in the WHO INN list, to facilitate consistent identification across countries

• Development code: LY3437943 — this alphanumeric identifier was assigned by Eli Lilly and Company, the pharmaceutical manufacturer developing the compound, and is frequently used in clinical trial documentation and scientific publications

• Descriptive terms: Sometimes referred to informally in research contexts as a GLP-1/GIP/glucagon triple agonist or a triagonist, though these are descriptive terms rather than formal names

No proprietary brand name (such as those used for semaglutide — Ozempic®, Wegovy® — or tirzepatide — Mounjaro®) has been officially assigned or approved for retatrutide at the time of writing. The absence of a retatrutide Summary of Product Characteristics (SmPC) on the Electronic Medicines Compendium (emc) further confirms its unlicensed status in the UK. Any references to brand names circulating online or on social media should be treated with caution, as these are not officially sanctioned.

For those searching for information, LY3437943 and retatrutide refer to the same investigational compound. Using the INN or development code when searching clinical trial databases will yield the most accurate and up-to-date study information. Relevant resources include:

• ClinicalTrials.gov — lists ongoing and completed trials globally, including Phase 3 studies of LY3437943

• EU Clinical Trials Register — covers trials conducted within the European Economic Area

• NIHR Be Part of Research (www.bepartofresearch.nihr.ac.uk) — the UK-facing resource for patients wishing to find and enquire about clinical trials in the United Kingdom

Retatrutide's Current Status in the UK and MHRA Approval Process

Retatrutide is unlicensed in the UK as of mid-2025 and is only available within authorised clinical trials. MHRA approval requires completion of Phase 3 trials, a Marketing Authorisation Application, and a subsequent NICE technology appraisal for NHS use.

As of mid-2025, no UK marketing authorisation has been granted for retatrutide. It remains an investigational medicinal product (IMP), meaning it is only available within the context of authorised clinical trials. The MHRA, which is responsible for evaluating the safety, quality, and efficacy of medicines in the UK, has not licensed retatrutide for any indication. The absence of a retatrutide SmPC on the Electronic Medicines Compendium (emc) is consistent with this unlicensed status.

Eli Lilly is currently conducting Phase 3 clinical trials — the large-scale studies required to demonstrate sufficient evidence of safety and efficacy before a regulatory submission can be made. These trials are evaluating retatrutide across several patient populations, including individuals with obesity, type 2 diabetes, and related metabolic conditions. Until these trials are completed and their data submitted to and reviewed by regulators, a formal approval timeline cannot be confirmed.

In the UK, the pathway to approval typically involves:

• Submission of a Marketing Authorisation Application (MAA) to the MHRA

• Scientific review of clinical trial data, including safety, efficacy, and quality data

• Benefit-risk assessment by MHRA experts

• If approved, a subsequent NICE technology appraisal to determine whether the medicine represents value for money and should be made available within the NHS

The MHRA also operates an Early Access to Medicines Scheme (EAMS), which can allow patients with life-threatening or seriously debilitating conditions to access promising unlicensed medicines before full approval. However, no EAMS designation is currently in place for retatrutide.

Patients should be aware that the approval process is rigorous and can take several years. There is currently no licensed route through which retatrutide can be prescribed or obtained in the UK outside of a clinical trial. Purchasing any product marketed as retatrutide from unregulated online sources carries significant safety risks and is strongly discouraged by the MHRA, which provides guidance on buying medicines safely online.

What Patients and Clinicians Should Know Before It Becomes Available

Retatrutide cannot be prescribed or legally obtained in the UK outside a clinical trial, and products sold online claiming to be retatrutide are unlicensed and potentially dangerous. Patients interested in trials should speak to their GP or search via NIHR Be Part of Research.

Given the significant public and clinical interest in retatrutide — driven largely by its early trial results — it is important that both patients and healthcare professionals approach this emerging therapy with informed caution. While the Phase 2 data are promising, several key considerations should be kept in mind ahead of any potential UK approval.

For patients:

• Retatrutide is not currently available on the NHS or through private prescription in the UK

• Products sold online claiming to be retatrutide are unlicensed and potentially dangerous — the MHRA advises against purchasing medicines from unregulated sources

• If you are interested in participating in a clinical trial, speak to your GP or specialist, who can advise on eligibility and refer you to appropriate research centres; you can also search for UK trials via NIHR Be Part of Research (www.bepartofresearch.nihr.ac.uk)

• Do not discontinue any existing prescribed medication (such as semaglutide or tirzepatide) in anticipation of retatrutide becoming available

For clinicians:

• Familiarise yourself with the LY3437943 development code and ongoing Phase 3 trial data, as patients may present with questions informed by media coverage

• Be prepared to discuss the distinction between investigational and approved therapies, and the importance of evidence-based prescribing

• Monitor MHRA and NICE communications for updates on regulatory submissions and technology appraisals

From a safety perspective, the adverse effect profile observed in Phase 2 trials (as reported in the 2023 New England Journal of Medicine publication) was broadly consistent with other GLP-1-based therapies, with nausea, vomiting, diarrhoea, and decreased appetite being the most commonly reported side effects. Serious adverse events were infrequent in the short term. However, long-term safety data — including cardiovascular outcomes, heart-rate effects, and optimal dosing — are still being gathered in Phase 3 studies, and no definitive safety conclusions can be drawn at this stage.

If you are participating in a clinical trial and experience a suspected side effect, you should report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Healthcare professionals and members of the public can both submit reports.

In summary, retatrutide — also known by its development code LY3437943 — represents a potentially significant area of investigation in metabolic medicine. Patients and clinicians alike should await full regulatory review and, where appropriate, NICE appraisal before drawing firm conclusions about its place in therapy.

Frequently Asked Questions